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Editor: L. LeiboviciTo the editor,
Wewould like to explain several points raised by Vedrines et al.
1. We agree that Geleris et al. used a composite endpoint [1].
However, (a) intubation is a main prognostic factor for death, (b)
exclusion of this study from the pooled RR estimation did not
change our conclusion (see Table S4) and (c) Geleris et al. did not
report adjusted hazard ratio (HRa) for death only.
In our main analysis, we used this adjusted HR which takes into
account indication bias (following the Cochrane recommendation
[2]). Crude relative risk (RR) for death only may be estimated from
the data reported in Geleris et al.: with 157 deaths among the
hydroxychloroquine group (n ¼ 811) and 75 deaths among the
control group (n ¼ 565), the new estimated RR is even higher: 1.45
(95% CI 1.13e1.87).* Corresponding author. Thibault Fiolet, Center for Research in Epidemiology and
Population Health Inserm U1018 “Health across Generations” Team and Paris-Sud
11 University/Paris-Saclay University, 114 rue Edouard Vaillant, 94805 Villejuif
Cedex, France.
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biased data on the overall population (n ¼ 807) [3,4]. The sub-
analysis among patients who were admitted during the first
4 weeks of study, discussed by Vedrines et al. represents half of
the initial cohort: that is why we used the HR reported in their
main analysis.
Using the HR from the subgroup cohort and the new HR for
Geleris et al. leads to similar results with the pooled RR¼ 0.82 (95%
CI 0.64e1.04) for hydroxychloroquine (HCQ) (Fig. S1) and RR ¼ 1.23
(95% CI 1e1.53) for HCQ þ azithromycin (AZI) (Fig. S2), indicating
no benefit from HCQ with or without AZI. We thank Vedrines et al.
for leaving us the opportunity to illustrate again the robustness of
our conclusion.
3. The point concerning Rivera et al. was already answered [5]. We
note that this is the second letter from Dr Lacout, which is quite
uncommon for the same study.
4. The Arshad et al. study was excluded from our main analysis
because of numerous critical biases described in our supple-
mentary materials and in two letters and one editorial [6e9].
Briefly, this study suffers from immortal time bias and residual
confounding, and it is not possible to know if the observed risk
reduction is due tohydroxychloroquineor corticosteroids use. Finally,
Vedrines et al. may be interested by the sensitivity analysis including
studies at risk of critical bias, whichwas provided in our Table S6 [10].
5. The statement that we misrepresented four original works is
fallacious.
Nevertheless, we agree with Vedrines et al. on one point: even
if we carefully evaluated all studies of our systematic reviewublished by Elsevier Ltd. All rights reserved.
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according to PRISMA guidelines, observational studies are not the
reference standard for therapeutic evaluation. Since our work was
published, several other randomized controlled trials have become
available. Overall, the RECOVERY trial, the SOLIDARITY trial and
recent meta-analyses confirmed our conclusion [10e16]: hydrox-
ychloroquine was not associated with a decrease in mortality for
hospitalized patients. The Axfors et al. meta-analysis, based on 26
published and unpublished RCTs (including SOLIDARITY and RE-
COVERY trials), found a significant increased risk for mortality
[14]. Thus, there is no need to reconsider our conclusion. We
advise Vedrines et al. to consider the last published articles and
evidence. Vedrines et al. stated that reality is complex. We agree,
and we add that because reality is complex solid evidence of a
favourable benefiterisk ratio is necessary. The COVID-19 crisis
does not make the need for rigorous science obsolete: it reinforces
this need.
As stated by the author of a recent editorial on studies evalu-
ating tocilizumab, another putative treatment for COVID-19 pa-
tients, “I plan to wait out the torrent of positive observational
studies and reconsider tocilizumab's use in COVID-19 if, and only if,
more compelling data from randomized trials emerges.” Regarding
hydroxychloroquine, the torrent of positive observational studies,
often of very low quality, has been shared, but compelling data
from randomized trials have already been published and are
univocal: hydroxychloroquine with or without azithromycin is not
an effective treatment for patients with COVID-19 [17].
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.cmi.2020.10.031.
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